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Patient 1. A 42-year-old woman first was evaluated at the New
England Medical Center after an episode of dysuria that resolved
following treatment with an antibiotic. Her weight was 55.5 kg and the
blood pressure was 150/100 mm Hg. Urinalysis disclosed 3+ protein,
5—15 red blood cells/high-power field, occasional granular casts, and
oval fat bodies. A 24-hour urine sample contained 3.9 g protein and 820
mg creatinine. Serum creatinine was I. I mg/dl and creatinine clearance
was 52 mI/mm. Because of the laboratory abnormalities, a mild senso-
rineural hearing loss bilaterally, and a family history of renal disease, a
diagnosis of hereditary nephritis was made. Hypertension was treated
with hydrochlorothiazide, During the next 3 years, her blood pressure
was usually in the range of 130/95 mm Hg, but occasional values were
as high as 180/110 mm Hg. Urinary protein excretion declined to 0.64
glday. She complained of nocturia but otherwise was asymptomatic.
At age 45 years, her blood pressure was 160/85 mm Hg and serum
creatinine was 2.2 mg/dI. Propranolol, 20 mg twice daily, was added to
her regimen, and a 40 g protein diet was prescribed. During the next 4
years, her hypertension was treated with hydrochlorothiazide, 50
mg/day; atenolol, 50 mg/day; and captopril, 25 mg/day; her blood
pressure was usually in the range of 130—140/80—90 mm Hg. Body
weight and serum albumin concentration remained stable. Serum cre-
atinine ranged from 2.2 to 2.5 mg/dl.
At age 49 years, she entered the feasibility phase of the Modification
of Diet in Renal Disease (MDRD) Study. She was randomly assigned to
follow a very low protein diet (16 g/day, equivalent to 0.28 g of
protein/kg ideal body weight/day) supplemented with 12 g/day of an
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essential amino acid mixture and high-calorie, low-protein nutritional
supplements. Her antihypertensive medications were not changed.
Dietary protein intake, estimated from measurements of 24-hour uri-
nary urea excretion, ranged from 0.3 to 0.5 g/kg/day. Her weight
decreased by 2 kg, and the serum albumin and transferrin concentra-
tions were stable. Table I shows detailed renal function measurements
during a 9-month interval.
At age 51 years, at the conclusion of the feasibility phase of the
MDRD Study, a 40 g protein diet was resumed. During the following
year, she remained relatively asymptomatic. Blood pressure has been in
the range of 110—130/80—90 mm Hg while she has been taking hydro-
chlorothiazide, 50 mg/day, and captopril, 25 mg/day. Her weight has
declined by an additional 4 kg. At the time of her most recent visit, the
serum albumin was 4.1 g/dl; serum creatinine was 2.2 mg/dl, and
24-hour urine protein excretion was 0.12 g/day.
Patient 2. A 55-year-old man was found to have renal disease after an
evaluation for urethral burning during ejaculation. Urinalysis disclosed
2+ protein, and the serum creatinine was 1.5 mg/dl. He had had several
prolonged hospitalizations 2 years earlier for multiple trauma from a
motor vehicle accident and postoperative complications, including
acute tubular necrosis.
He was evaluated at New England Medical Center at age 58 because
of an elevated serum creatinine. His weight was 106.8 kg and blood
pressure was 138/86 mm Hg. Urinalysis revealed 3+ protein, 2—5 red
blood cells/high-power field, and 2—3 granular casts/low-power field. A
24-hour urine sample contained 3.1 g protein and 1100 mg creatinine.
The serum creatinine was 2.3 mg/dl and creatinine clearance 33 mI/mm.
Renal biopsy showed focal and segmental glomerulosclerosis. One year
later, the patient enrolled in the feasibility phase of the MDRD Study.
He was randomly assigned to follow a very low protein diet (22.4 g/day,
equivalent to 0.28 g protein/kg ideal body weight/day) supplemented
with 22 glday of a mixture of essential and nonessential ketoacids and
high-calorie, low-protein nutritional supplements. His blood pressure
was in the range of 130—160/80—90 mm Hg without antihypertensive
medications. Dietary protein intake, estimated from measurements of
24-hour urinary urea excretion, averaged 0.5—0.6 g/kg/day. His weight
remained stable, as did the serum albumin and transferrin concentra-
tions. Table 1 shows detailed renal function measurements during a
6-month interval.
At the conclusion of the feasibility phase of the MDRD Study, when
he was age 61 years, a low-protein diet (52 g/day) was recommended.
Over the next 5 months, his blood pressure rose to 160—170/90—100 mm
Hg, and the serum creatinine increased to 7.4 mgldl. He suffered
multiple injuries in another motor vehicle accident and required hemo-
dialysis for treatment of severe azotemia. He remains dialysis depen-
dent.
Discussion
DR. ANDREW S. LEVEY (Director, Nephrology clinical Re-
search Center, Division of Nephrology, New England Medical
Center, and Associate Professor of Medicine, Tufts University
School of Medicine, Boston, Massachusetts): These two case
histories illustrate several important points about the assess-
ment of renal function during progressive renal disease. First,
during the short period of followup in the MDRD Study, both
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Table 1. Selected renal function data dun ng one year of foilowup in the MDRD Studya
GFR Ccr Car — GFR
Time from
initial visit
cr
mg/dl
mi/mini
/ .73 m2
mi/mini
1.73 m2
UcrV
mg/day
TScr
mg/day
mi/mini
1.73 m2 CCIJGFR
Patient I
2.5 19 18 585 —27 —1 .95
3 mos. 2.5 14 24 801 339 10 1.71
6mos. 2.6 13 29 987 538 16 2.23
9mos. 2.5 12 23 759 363 11 1.92
Patient 2
0 2.4 35 32 1484 —140 —3 .91
3mos. 2.4 28 31 1438 159 3 1.11
6mos. 2.7 22 25 1285 157 3 1.14
a Abbreviations: cr' serum creatinine; GFR, glomerular filtration rate; Car, creatinine clearance; UcrV, renal creatinine excretion; TSar, tubular
secretion of creatinine.
patients experienced a progressive decline in renal function as
assessed by glomerular filtration rate (GFR) (Table 1). Second,
despite similar serum creatinine values (Per), the level of renal
function differed markedly between the two patients. Third,
despite a relatively stable the GFR declined steadily both
patients. Fourth, the urinary creatinine excretion differed be-
tween the 2 patients and was variable over time. Fifth, tubular
secretion of creatinine was variable; hence, the relationship
between creatinine clearance and GFR, expressed as either the
difference between the measurements or the ratio of the mea-
surements, also was variable.
Unfortunately, these 2 patients are not unusual; many com-
mon renal diseases progress to renal failure, often for unclear
reasons. In experimentai animals with renal diseases, initial
renal injury can be self perpetuating by several pathways [1, 2]
and can result in progressive renal failure. Additional experi-
mental evidence suggesting that these pathways can be inter-
rupted has raised the hope that someday we will be able to halt
or delay the progression of chronic renal disease in humans.
These observations in animals hwe given rise to numerous
clinical trials. Because the decline in renal function in most
chronic renal diseases is slow, however, it is not practical to
assess the effect of an intervention by determining the time
elapsed before renal failure ensues. For this reason, many
investigators have evaluated the effectiveness of therapy by
measuring the rate of decline in renal function. The most
popular method is measurement of the rate of decline in the
reciprocal of the serum creatinine concentration (1'1cr)'assum-
ing that this measure reflects the rate of decline in creatinine
clearance and hence in GFR [3, 4]. Using this method, several
investigators have concluded that low-protein and low-phos-
phorus diets can retard the progression of renal disease [5—9].
As a result, many nephrologists have adopted dietary modifi-
cation as routine therapy for patients with chronic renal dis-
ease.
The goal of my discussion is to analyze the utility and
limitations of measuring GFR and l/Pcr to assess the level of
renal function and rate of progression. I will focus on three
topics: (1) GFR as an index of renal function; (2) the relation-
ship between GFR and 1/Pc,.; and (3) applications of the rate of
decline in renal function in studies of the progression of renal
disease. I will conclude that Pa,. and lfPcr provide a rough index
of GFR, but that the rate of decline in l/P. may not accurately
reflect the rate of decline in GFR. I will suggest that conclusions
from the studies of the effectiveness of low-protein and low-
phosphorus diets, in which the rate of decline in 1/Pc,. is the
principal measure of the rate of progression, are not definitive.
Finally, I will suggest that future studies should include mea-
surements of GFR, and that other features of the design of
clinical trials, such as selection of patients, length of followup,
and sample size, are equally important in identifying therapies
that can retard the progression of renal disease.
GFR as an index of renal function
The usefulness of any diagnostic test is based on its accuracy
(comparison to a standard), precision (related inversely to the
variability of measurements), and convenience. In clinical
practice, physicians use test results to characterize the degree
of functional abnormalities in individual patients; tests are
repeated to assess changes in individuals over time. In clinical
trials, investigators use test results to characterize a study
population; repeated evaluations are performed to assess
changes in the population over time. The decision to use a
particular test depends on features of the test, features of the
subjt cts to be tested, and the seuing in which the test is used.
The rate of glomerular filtration generally is believed to be the
best oveall index of renal function in health and disease.
Interestingly, this belief, although widely held, has not been
subjected to formal evaluation. Attributes of the GFR as an
overall index include the following: (I) It is a direct measure of
renal function f10]. (2) It is reduced prior to the onset of
symptoms of renal failure [11]. (3)In chronic renal diseases, the
reduction in GFR correlates with the severity of some of the
structural features of the end-stage kidney, such as the extent of
tubulointerstitial sclerosis [12, 131. (4) Signs and symptoms of
uremia appear when GFR falls below 5—10 mI/mm, even when
azotemia, acidosis, hypocalcemia, phosphate retention, and
anemia are corrected. But there are pitfalls in using the GFR as
an index of renal function. First, the measurements are difficult
to perform. Second, estimates of GFR can be imprecise. Third,
GFR can be relatively insensitive for detecting early renal
disease and for monitoring its progression.
Performance of GFR measurements. Rigorous assessment of
GFR requires the measurement of renal clearance, utilizing an
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ideal filtration marker. Inulin, a 5200 dalton polymer of fruc-
tose, fulfills the criteria for an ideal filtration marker and is the
standard against which other markers are compared [14]. The
classical method of Homer Smith included continuous intrave-
nous infusion of inulin, urine collection by bladder catheteriza-
tion, and measurement under standard conditions; subjects
were studied while lying down the morning after an overnight
fast [10]. However, the classical inulin clearance method is not
practical either for clinical practice or clinical research. Inulin
currently is in short supply, and it is difficult to measure.
As a consequence, alternative filtration markers and clearance
methods have been developed and validated. The most widely
used alternative filtration markers in the United States are
'251-iothalamate and mTcdiethylenetriaminepentaacetic acid
(DTPA). Both iothalamate and DTPA are excreted almost
entirely by glomerular filtration. Radionuclide labeling permits
accurate detection of minute doses of the marker in plasma and
urine, and little of the radionuclide dissociates from the marker.
The '251-iothalamate is administered as either a subcutaneous or
intravenous bolus; 99mTc DTPA is administered as an intrave-
nous bolus. Because urine is collected by spontaneous voiding,
its flow rate is stimulated by water loading to reduce the
possibility of error due to incomplete emptying of the bladder.
Simultaneous measurements of renal clearance of '251-iothala-
mate and mTcDTPA by these methods, and of inulin by
standard techniques, reveal similar results [lS—231.
Although not available in the United States, 51Cr-ethylenedi-
aminetetra-acetic acid (EDTA) is widely used as a filtration
marker in Europe. Plasma clearance typically is measured to
avoid the need for urine collections. Simultaneous measure-
ments of renal inulin clearance and plasma 51Cr-EDTA clear-
ance yield similar results, but this similarity derives from a
coincidence of two errors: underestimation of renal inulin
clearance by renal 51Cr-EDTA clearance and overestimation of
renal 51Cr-EDTA clearance by plasma 51Cr-EDTA clearance
[23—32].
Radiation exposure is minimal with all three isotopes. In
general, one chooses a filtration marker according to the ease of
obtaining, administering, and counting the radioisotope. In an
effort to avoid exposing patients to radiation, some investiga-
tors have performed clearance procedures using minute doses
of nonradioactive iothalamate (Conray) or diatrizoate meglu-
mine (Hypaque) and high-performance liquid chromatography
to measure plasma and urine samples [33, 34]. These methods
require expensive and time-consuming laboratory techniques,
however.
Precision of estimates of GFR in humans. Clearance mea-
surements can be used to estimate GFR of an individual or of a
study population. In an individual, the precision of the estimate
is influenced by variability in the assessment of urine and
plasma concentrations of the filtration marker, variability in
renal function during multiple urine collection periods during a
single clearance procedure, and variability in renal function
from one clearance procedure to the next. Within a study
population, the estimate is influenced additionally by variability
in renal function among individuals. I will focus on the variabil-
ity in renal function from time to time in individuals and on the
variability in renal function within a study population. Table 2
compares the variability of measurements of GFR and serum
creatinine in humans, expressed as the ratio of the standard
Table 2. Comparison of coefficients of variation (CV) and critical
differences (CD) for measurements of GFR and serum creatinine (Pcr)
Comparison of two measurements in a single individual
Renal CV CD
function Measurement % %
Normal GFR 7.5 20
Normal Pcr 11.0 31
Reduceda GFR 12.0 33
Reduced cr 6.3
Comparison of two individuals
18
Renal CV CD
function Measurement % %
Normal GFR 15 42
Normal cr 15 42
a Reduced renal function refers to GFR less than 30—50 mI/mm.
(From Refs. 16, 36, 37.)
deviation to the mean (that is, the coefficient of variation [CV]).
Also included is the minimal difference (that is, the critical
difference [CD]) between measurements that is necessary for
the difference to be statistically significant [35]. For all mea-
surements, the greater the variability, the less precise the
estimate of the level of renal function, and the greater the
required difference between estimates for statistical signifi-
cance.
First, consider time-to-time variability in an individual. As
the top half of Table 2 shows, the CV of measurements of GFR
and serum creatinine depend on the level of renal function [16,
36, 37],* In individuals with normal renal function, the CV is
7.5% for GFR and 11% for serum creatinine, whereas in
individuals with reduced renal function (GFR less than 30—50
mi/mm), the CV is 12% for GFR, but only 6.3% for serum
creatinine. As a result, within the normal range of renal
function, the CD for measurements of GFR would be less than
that for serum creatinine; hence, in comparing the level of renal
function in a normal individual at two separate times, GFR
measurements would be more precise than would measure-
ments of the serum creatinine. In patients with reduced renal
function, however, the CD for measurements of serum creati-
nine would be less than that for GFR; that is, measurements of
serum creatinine would be more precise.
Second, consider variability among individuals. As shown in
the bottom half of Table 2, in the normal population, the CVs
for GFR (adjusted for age, gender, and body size) and serum
creatinine (adjusted for gender) are both approximately 15%
[38, 39]. In comparing two individuals with nearly normal renal
function, then, the CD between measurements of either GFR or
serum creatinine would be 42%. It is important to note that
variability in measurements of renal function among normal
* In the study of individuals with normal renal function, urine was
collected by bladder catheterization, with an average CV between
collection periods of only 7.5% [36). In the study of patients with renal
disease, urine was collected by spontaneous voiding, with an average
CV between collection periods of 20% [16). Hence, the higher CV
between measurements that was observed in patients with renal disease
might be due, in part, to the higher CV among collection periods as a
result of different methods of urine collection.
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Table 3. Effect of variability and hypothesized difference in renal
function in two groups on sample size requirement to detect the
differencea
Variability in renal function
in each group
Hypothesized differences in
mean level of renal function
between two groups
CV 10% 20% 50%
15% 80 20 <10
25% 200 40 10
50% 600 300 30
a Sample size is the total number of patients, divided into two groups,
that must be included in a clinical trial to detect a hypothesized
difference between the groups, CV is the coefficient of variation among
patients included in the trial (assumed to be equal in both groups).
Calculations are performed for an alpha error of 0.05 (two-sided) and a
beta error of 0.20 (one-sided) [40].
individuals is greater than the variability in repeated measure-
ments in a single individual, irrespective of the renal function
parameter that is measured.
Among patients with renal disease, variability in renal func-
tion is influenced additionally by criteria used to select the
patients. For example, in the studies of low-protein and low-
phosphorus diets that I mentioned earlier, the CV of serum
creatinine among patients selected ranged from approximately
5% to 30% [5—9]. As shown in Table 3, variability in renal
function within a study population has an important effect on
the design of a clinical trial to determine the efficacy of therapy
for renal disease. The number of patients (sample size) required
to detect a difference between two groups depends on the
hypothesized difference between the groups, the desired statis-
tical power of the analysis, and the variability among patients
[40]. For a given degree of statistical power, the greater the CV
among patients or the smaller the hypothesized difference
between groups, the greater the required sample size, irrespec-
tive of the measure of renal function that is used. These
considerations emphasize the importance of variability among
individuals and patient selection criteria, as well as the choice
of renal function measurements in the design of clinical trials.
Sensitivity of GFR measurements. In principle, GFR is the
sum of the filtration rates of all nephrons. The following
equation depicts the determinants of single-nephron GFR
(SNGFR):
SNGFR = KF'P
SNGFR A 'P(PH — P0)
where K is the ultrafiltration coefficient, defined as the product
of glomerular surface area (A) available for filtration and its
hydraulic permeability (P); and zP is the net filtration pressure,
defined as the difference between the transglomerular hydro-
static (PH) and oncotic (P0) pressure gradients. These gra-
dients are affected, in turn, by the level of renal blood flow and
afferent and efferent glomerular arteriolar resistances [41].
From this equation, it is clear that a decrease in either
glomerular capillary surface area or permeability can reduce the
GFR. It is also clear, however, that alterations in arteriolar
resistances could lead to a countervailing alteration in filtration
pressure that might stabilize SNGFR despite glomerular injury.
For example, the earliest alteration in the determinants of
SNGFR might be reduced hydraulic permeability due to dam-
age to the glomerular capillary wall; an increase in glomerular
capillary surface area (from perfusion of previously unperfused
capillary channels or from glomerular hypertrophy) would
maintain K and thus SNGFR. Once KF declines, increased
iP and reduced P0 from augmented glomerular perfusion
might maintain SNGFR. Once SNGFR declines, these same
effects in undamaged nephrons might maintain whole-kidney
GFR. These alterations have been observed in experimental
animals and likely occur in humans with progressive renal
diseases [42]. Hence, measurement of GFR might not reveal the
extent of initial or subsequent structural gloinerular damage and
might not be a sufficiently sensitive index for detecting renal
disease or for assessing its progression.
Relationship between GFR and the reciprocal of the serum
creatinine concentration
The use of creatinine as an exogenous filtration marker was
first reported in 1926 [43]. Within 10 years, sensitive biochem-
ical assays were developed that permitted accurate quantitation
of creatinine concentrations in normal serum and measurement
of endogenous creatinine clearance [44]. These studies demon-
strated that creatinine is not an ideal filtration marker in
humans; it is excreted both by glomerular filtration and by
tubular secretion. Creatinine clearance thus would be expected
to overestimate GFR at all levels of renal function. Moreover,
some creatinine is excreted via extrarenal routes, and the rates
of renal and extrarenal excretion vary in patients with renal
disease. Hence, the relationship between creatinine clearance
and serum creatinine level varies; as a result, the relationship
between GFR and the serum creatinine level also varies. Figure
1 shows results from a representative study by Shemesh and
colleagues, in which simultaneous measurements of GFR by
inulin clearance, creatinine clearance, and serum creatinine
level were made in patients with glomerular diseases [20]. It is
clear from these data that neither the creatinine clearance nor
the serum creatinine level accurately estimates GFR. Indeed,
the sensitivity (proportion of true positives) of a reduced
creatinine clearance or elevated serum creatinine level in de-
tecting a reduced GFR was only 75% and 61%, respectively.
Nonetheless, the serum creatinine concentration remains the
most widely used measure of progression of renal disease in
clinical practice and in clinical trials. Arguments in favor of
using this measure follow:
(1) Accuracy. In assessing progression, it is necessary to
determine accurately the change in the level of renal function
rather than the exact level of function. Although the serum
creatinine level does not provide an accurate assessment of
GFR, some have claimed that changes in 1/Per are an accurate
reflection of changes in GFR [3, 4].
(2) Precision. As I said earlier, in patients with reduced renal
function, the time-to-time variability for the serum creatinine
level is lower than that for GFR. Hence, the serum creatinine
level is a more precise estimate of the level of renal function
than is GFR, and changes in serum creatinine level are easier to
detect than are changes in GFR.
(3) Convenience. The serum creatinine level is easily mea-
sured in all clinical laboratories. No special preparation is
necessary on the part of the patient or the laboratory. Measure-
ments thus can be made frequently and in all patients.
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Fig. 1. Relationships between GFR, C,,, and P,, in patients with glomerular disease. Vertical dashed lines in A and B correspond to the lower
limit for inulin clearance (82 mtfmin/I .73 m2); the horizontal line in A corresponds to the lower limit for creatinine clearance (77 mI/mm/I .73 m2);
the horizontal line in B corresponds to the upper limit for the serum creatinine concentration (1.4 mg/dl). The shaded areas include values for
patients in whom inulin clearance is reduced but creatinine clearance (A) or serum creatinine concentration (B) remains normal. (From Refs. 20
and 45.)
Clearly, the key argument is the first one. What follows is a
critical evaluation of the assumptions on which it is based.
Theoretical relationship between GFR and the reciprocal of
the serum creatinine concentration. Given that renal creatinine
excretion occurs by tubular secretion as well as by glomerular
filtration, the following equation can be derived:
UcrV GFR Pcr + TScr
where U,V is the rate of renal excretion and TS,. is the rate of
tubular secretion (usually given in mg/day). Creatinine is also
lost by extrarenal routes. Thus:
UrV = Gcr — Ecr
where Gcr is the rate of generation and Ecr is the rate of
extrarenal elimination (usually given in mglday).* If we rear-
range these formulas and solve for Pcr:
l/Pcr = GFRJ(Gcr — Ecr TScr)
Finally, the rate of change in lfP,. is obtained by differentiation
with respect to time, as shown in the equation below:
d/dt[lfPcr] = [l!(Gcr — Ecr — TS1)] 'd/dt[GFRI
+ GFR . d/dt{l/(Gcr — Ecr — TScr)]
* In an earlier publication, the term Ecr was used to represent clearance
of creatinine due to extrarenal elimination [45]. In this discussion,
extrarenal clearance is expressed as Ecr/Pcr.
Implicit in the use of the slope of the linear regression of lfPcr
versus time as an estimate of the rate of change in GFR in an
individual is the assumption that rates of change in both l/Pcr
and GFR are constant over time and are.related to each other by
a proportionality constant. Implicit in its use in a study popu-
lation is that the proportionality constant is the same for all
patients. These assumptions are valid only under certain con-
ditions:
(1) If the term Gcr — Ecr TScr is constant over time and
among patients, the following equations apply:
Gcr Ecr — TScr = k
= GFRJk
d/dt[l/Pcr] = (1/k) d/dt[GFRJ
This condition applies whether or not the individual terms Gcr,
Ecr, and TScr are constant.
(2) If the terms Gcr, Ecr/Pcr, and TSjPcr are constant over
time and among patients, the following equations apply:
Ger = k', Ec,JPcr k", TScr/Pcr k"
1/Per = (GFR + k" + k")/k'
d/dt[l/Pcrl = (1/k') d/dt[GFR]
In the following discussion, I will review previously pub-
lished studies suggesting that neither of these conditions is met.
Instead, the studies suggest that differences exist in tubular
secretion, extrarenal elimination, and rate of generation of
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>80 40-80 <40
42 50 81
113±32 60±7 22±9
134±45 94±23 42±18
21±45 34±23 20±18
1,16 1.57 1.92
creatinine among patients with chronic renal disease, and that
these parameters chinge over time. In each of the following
sections, I will illustrate the hypothetical effects of such differ-
ences among patients and changes over time on the rate of decline
in l/Pcr, despite an assumed constant rate of decline in GFR.
Effects of tubular secretion. Creatinine is secreted in the
proximal tubule by an active process that transports organic
cations [461. Drugs that inhibit creatinine secretion include
other organic cations, such as cimetidine and trimethoprim [47,
48], and probenecid, an organic anion [491. Inhibition of creat-
mine secretion reduces creatinine clearance and increases the
serum creatinine level without changing the GFR. Clinically, it
is important to distinguish drug-induced alterations in creatinine
clearance and serum creatinine level due to an inhibition of
creatinine secretion from those due to a reduction in GFR.
Most of the data regarding tubular secretion of creatinine in
humans are derived from cross-sectional studies (measure-
ments at one time only) in normal individuals and in patients
with chronic renal disease, such as the study by Shemesh and
colleagues (Fig. 1) [20]. Additional data from this study (Table
4) demonstrate the marked variability in the magnitude of
creatinine secretion among patients. The mean difference be-
tween creatinine clearance and GFR (the clearance of creati-
nine due to tubular secretion, that is, TSCIJPCr) and the mean
ratio of creatinine clearance to GFR differ in patients with
different levels of GFR. Moreover, at each level of GFR, the
variability among patients was high: the coefficient of variation
of creatjnine clearance due to tubular secretion was 2 14%, 68%,
and 90% among patients with GFR values that were greater
than 80, 40—80, and less than 40 mI/mm 1,73 m2, respectively.
Longitudinal studies also demonstrate that tubular secretion
varies widely in individual patients during the course of renal
disease [20, 50].
Figure 2 shows the effects of the tubular secretion of creati-
nine on the rate of change in 1/Pcr in 2 hypothetical patients, (a)
and (b), with declining GFR. The effect of differences between
patients is shown in the left panel. Values for TScr are constant
in both patients, but lower in (a) than in (b). Despite the same
rate of decline in GFR, the rate of decline in 1/Pc. is greater in
the patient with the higher TScr. The effect of changes over time
is shown in the right panel. Both patients have the same initial
TScr; however, in (a) TScr is constant, but in (b) TScr increases
as GFR declines. Despite the same rate of decline in GFR, the
rate of decline in l/Pcr is lower in the patient with increasing
TSr.
Effects of ext rarenal creatinine elimination. Creatinine is
eliminated almost entirely by renal excretion in humans with
normal renal function; negligible amounts are excreted in feces
and sweat [51, 52]. In patients with renal disease, however, the
renal excretion of creatinine is far lower than in normal mdi.-
viduals. Table 5 shows data from Goldman indicating that the
renal creatinine excretion is lower at all stages of chronic renal
disease, with lowest values occurring in patients with the most
severe reductions in renal function [52].
One reason for the reduced renal creatinine excretion is that
creatinine is also eliminated by extrarenal routes, probably
because of degradation by intestinal microorganisms [53, 54].
As I will mention in a moment, another possible reason is
decreased generation of creatinine. Table 6 illustrates the wide
range of values for extrarenal creatinine elimination [53, 54].
Despite the variability in Ecr, in one study, clearance of
creatinine due to extrarenal elimination (EciJPr) varied only
from 0 to 3.0 mI/mm, and Ecr significantly correlated with cr (r
=
.69), indicating that EciiPcr was relatively constant among
this group of patients [54].
Figure 3 shows the effects of the rate of extrarenal elimination
of creatinine on the rate of change in 1IP in 4 hypothetical
patients, (a) through (d), with declining GFR. The effect of
differences among patients is shown in the left panel. The rate
of extrarenal creatinine elimination is lowest in (a) and highest
in (d). Despite the same rate of decline in GFR, the rate of
decline in 1/Per is least in the patient with the lowest extrarenal
elimination rate. The right panel shows the effect of changes
over time. Extrarenal creatinine elimination is un ;hanged in (a)
and increases most in (d). Despite the same rate of decline in
GFR, the rate of decline in l/Pcr is least in the patient with the
greatest increase in extrarenal elimination.
Effects of creatinine generation. Creatinine generation is
defined as the entry of creatinine into body fluids from endog-
enous or exogenous sources. Endogenous creatinine is the final
breakdown product of creatine metabolism. After synthesis
from amino acid precursors or absorption from the gastrointes-
tinal tract, creatine is concentrated in muscle, stored as creatine
and phosphocreatine, and converted to creatinine. Exogenous
creatinine originates from dietary ingestion. Thus, the rate of
creatinine generation is affected by muscle metabolism and diet.
Generation of creatinine from creatine depends on the size of
the creatine pool and its rate of turnover to creatinine [55].
Approximately 98% of creatine and phosphocreatine is con-
tained in muscle; the total body creatine pool thus is related to
muscle mass. In a healthy 70 kg young man, for example, the
total body creatine pool is approximately 100 g to 120 g. Daily
creatine turnover has been estimated to be only 1.6% to 1.7% of
the total pool. Therefore, in a steady state of creatinine balance,
the creatinine generation rate from muscle metabolism would
be 1700 to 2000 mg/day.
Muscle mass is related to age, weight, and gender. Accord-
ingly, differences in creatine pool and in creatinine generation
rate among individuals are to be expected. Walser recently
summarized the data on renal creatinine excretion from 5
reports on 1100 healthy individuals and patients without renal
or hepatic disease [56]. (In these subjects, creatinine excretion
is expected to equal the creatinine generation rate.) He calcu-
lated that the renal creatinine excretion (UCrV, mg/kg/day) is
related to age (years) as follows:
UcrV = 28.2 — 0.172 x age (men)
UcrV = 21.9 — 0.115 x age (women)
Table 4. Effect of level of renal function on tubular secretion of
creatinine in glomerular diseasea
Range of GFRb
Patients (n)
GFR (M SD)
Ccr (M SD)b
Cer - GFR (M SD)
CCrJGFR (M)
_________
a From Ref. 20.
b Values for GFR and Ccr are given as ml/minll.73 m2.
Table 5. Creatinine excretion in chronic renal diseasea
"Cr Ccr t'cr IJ0rV
range Patients mean mean mean SD
(mg/dl) (n) (mi/mm) (mg/d[) (mg/day)
<2.0 85 85.1 1.16 1320 420
2.0—4.0 29 29.9 2.95 1200 430
4.0—6.0 17 16.5 4.84 1110 470
>6.0 22 6.4 10.37 880 380
a From Ref. 52.
Alterations in the rate of creatinine generation also can arise
from changes in the size of the pool or the rate of turnover of
creatine. In conditions associated with muscle wasting, such as
inflammatory and degenerative diseases, and in malnutrition,
creatine turnover can be increased [57—60]; this rise initially can
lead to an increased creatinine generation rate, but subse-
quently to reduced muscle mass and decreased creatinine
generation.
Finally, the creatinine generation rate also is affected by
dietary intake of exogenous creatine and creatinine, derived
largely from ingestion of meat. The creatine content of meat
ranges from 3.5 to 5.0 mglg, of which as much as 65% can be
converted to creatinine during cooking [61, 62). Ingested cre-
atine and creatinine both are absorbed by the gastrointestinal
Table 6. Extrarenal elimination of creatinine in chronic renal
diseasea
Patients (n) 8b 9C
Range of Ccr (mi/mm) 23d 1.90—10
Range of Cr (mg/dO 6.6—18 6.3—24
Range of Ecr (mg/day) 312—715 0—797
Range of Gcr (mg/day) 776—1752 1017—1921
Range of Ec,/Gcr (%)
Range of Ec,JPcr (m1/mi,)
16—66
12_70d
0—56
0—3.0
a Abbreviations: Cçr, creatinine clearance; "Cr, serum creatinine
level; Ecr, rate of extrarenal elimination of creatinine; Ger, rate of
generation of creatinine.
' From Ref. 53.
C From Ref. 54.
d Values from 5 patients who were not being dialyzed.
tract. Therefore, in principle, alterations in meat intake affect
the creatinine generation rate by altering the total body pool of
both creatine and creatinine.
Crim, Calloway, and Margen demonstrated that ingestion of
a creatine supplement expands the creatine pool and increases
renal creatjnjne excretion, and conversely, that eliminating
creatine from the diet contracts the creatine pool and reduces
renal creatinine excretion [63, 64]. These changes in the cre-
atine pool and in renal creatinine excretion occur without
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Fig. 2. Effects of differences between patients and changes over time in TSr on the rate of decline in I/PC,. Values for initial and final GFR, TSCr,
FLcr, (rate of creatinine filtration, defined as GFR 1'cr), UcrV, Ccr, and CCr/GFR are illustrated for two hypothetical patients, (a) and (b). In both
patients, U,V is constant at 1730 mg/day throughout the 2-year interval. In the left panel, values for TS are different but constant. In (a) TS
is 430 mg/day, whereas in (b) TScr is 690 mg/day. As a result, the ratio of CCI./GFR is 1.33 in (a) and 1.67 in (b). Consequently, initial and final values
for lfP. are higher in (b) than in (a), and the rate of decline in lIPcr is greater in (b) than in (a). In the right panel, the 2 patients have the same
initial TScr, 430 mg/day, resulting in an initial ratio of CC,JGFR of 1.33. In (a) the rate is constant, but in (b) the rate increases to 690 mg/day as
GFR declines, resulting in a final ratio of CCIJGFR of 1.67. Consequently, the final value of 1/Pcr is higher and the rate of decline in 1/PCC is lower
in (b) than in (a).
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concurrent alterations in nitrogen balance or total muscle mass.
Figure 4, from studies by Bleiler and Schedl [65], shows the
decline in renal creatinine excretion and serum creatinine
following elimination of meat from the diet and the substitution
of a creatine-free protein formula (casein). Because of the low
turnover rate of creatine, the changes evolve over weeks
following the change in dietary creatine. On the other hand,
ingested creatinine rapidly increases serum and urinary creati-
nine levels [66, 67]. Figure 5 shows the effect of a meat meal on
serum creatinine [67]. Given that the creatinine content of
cooked beef can be as high as 3 mg!g, ingestion of one
quarter-pound hamburger could increase the renal creatinine
excretion by 350 mg.
Few data are available on creatinine generation in patients
with chronic renal disease. As I mentioned previously, renal
creatinine excretion is lower than expected in patients with
chronic renal disease, possibly because of decreased creatinine
generation. In studies I referred to earlier, creatinine generation
was within the expected range for normal individuals, and the
increase in extrarenal creatinine elimination accounted for the
reduction in its urinary excretion [53, 541. Indeed, Mitch and
Walser hypothesized that creatinine generation is normal
throughout the course of chronic renal disease and that in-
creased extrarenal excretion can fully account for the decline in
renal excretion [68]. However, dietary protein restriction, ano-
rexia, and weight loss in patients with chronic renal disease are
likely associated with reduced meat intake and muscle mass,
and these reductions would be expected to decrease creatinine
generation.
Figure 6 shows the effect of creatinine generation on the rate
of change in l/P0r in hypothetical patients who have declining
GFRs. The effect of differences among 4 patients, (a) through
(d), is shown in the left panel. Creatinine generation is highest
in (a) and lowest in (d). Despite the same rate of decline in GFR,
the rate of decline in l/Pr is least in the patient with the highest
Gcr. The effect of changes over time is shown in the middle and
right panels. In the middle panel, Gcr is constant in (a) but
declines gradually in (b). Despite the same rate of decline in
GFR, the rate of decline in lIPr is lower in the patient with
declining Gcr. In the right panel, the 2-year followup interval is
divided into three 8-month periods. The Gcr is again constant in
(a). In (b), however, the Gcr is constant during the first period,
declines gradually during the second period, and remains con-
stant at a lower value during the third period. The rate of
decline in l/Pc is initially the same as in (a), but subsequently
it is slower and then faster than in (a). Thus, despite a constant
rate of decline in GFR, the rate of decline in l/Pcr changes if
creatinine generation changes.
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Fig. 4. Effect of elimination of meat from the diet and substitution of
creatine-free protein formula. Serum and urinary creatinine and creat-
mine clearance, measured at weekly intervals, are shown in 6 healthy
subjects. (From Ref. 65.)
Observations on the relationship between rates of decline in
the reciprocal of the serum creatinine and GFR. Thus far, only
limited data are available on the relationship between rates of
decline in i/Per and GFR. In three separate reports, the corre-
lation in groups of patients was relatively weak: the proportion
of variability in rates of decline in l/Pr that can be attributed to
variability in rates of decline in GFR was only 0.14 to 0.52
[69—7l]. These results demonstrate that the rate of decline in
i/Pcr is not an accurate measure of the rate of decline in GFR
during short-term (one- to two-year) studies. One possible
explanation for these relatively weak correlations, as I said, is
that tubular secretion, extrarenal elimination, and generation of
creatinine differ among patients and change over time in a given
patient. Other explanations also are possible, however. First,
rates of decline in both GFR and 1/Per might not have been
constant throughout the followup interval. Indeed, even if the
rate of decline in GFR were constant, the studies I have
reviewed suggest that the theoretical conditions for a constant
decline in "Crwere not met. Second, the estimates of the rates
of decline in GFR and cr may not have been precise. The
studies reported so far are characterized by small absolute
changes in renal function, a limited number of measurements.
and short followup intervals. These factors might result in
imprecise estimates of the rates of decline in GFR and 1IP and
therefore might weaken the correlation between them. Longer
periods of followup might be necessary for more precise esti-
mates and for satisfactory correlations.
In summary, the theoretical analysis and observed correla-
tions suggest that the rate of decline in 1/Per is affected by
several factors other than the rate of decline in GFR, including
tubular secretion, extrarenal elimination, and generation of
1.2 -
1.0-
0.8
creatinine. These factors are highly variable among patients
with renal disease and change as renal disease progresses. As a
result, differences among patients in the rate of decline in i/Per
do not necessarily represent differences in the rate of decline in
GFR. Similarly, changes over time in the rate of decline in l/P1
in individual patients need not represent changes in the rate of
decline in GFR. These conclusions challenge the argument that
changes in i/Per accurately reflect changes in GFR. Further-
more, they raise questions about the validity of the conclusions
of the aforementioned studies of low-protein and low-phos-
phorus diets on the progression of renal disease.
Applications of the rate of decline in renal function in studies
of the progression of renal disease
Thus far, I have concentrated on the use of measurements of
GFR and 1/Pa. to estimate the rate of decline in renal function.
In this section, I will focus on methodologic limitations in
applying this estimate, irrespective of the measure of renal
function that is used, to studies of the progression of renal
disease. The estimated rate of decline in renal function can be
applied in one of two general ways: (1) In an individual patient,
rates during different periods of time can be compared; changes
in the rate are associated with changes in the patient's disease
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Fig. 5. Effect of meat intake on plasma creatinine concentration in 6
healthy subjects. Solid circles represent values after a meal containing
cooked meat protein. Open circles represent values after a meal devoid
of meat protein. (From Ref. 67.)
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or treatment. Typically, in this type of study, patients serve as
their own controls. (2) In groups of patients, the mean rates can
be compared; differences in rates are associated with differ-
ences in the patients' diseases or treatments. In this type of
study, one group serves as the control for another. The princi-
pal methodologic limitations of these applications derive from
the assumption of a constant rate of decline in renal function in
an individual patient and from variability in the rates of decline
among patients. In the following discussion, I will explain these
limitations as well as the implications on the design of clinical
studies.
Assumption of a constant rate of decline in renal function.
The use of linear regression analysis to estimate the rate of
decline in renal function rests on the assumption that the
decline in renal function over time is linear, that is, that the rate
of decline is constant. Constancy of the rate of decline in renal
function can be assessed, in part, from the correlation of renal
function and time. Although no statistical test can prove that
the observed relationship is truly linear, a high correlation
suggests that the regression line is a reasonable description of
the true relationship.
Mitch and colleagues were the first to recognize the strong
correlation between 1/P01. and time [72]. Since then, numerous
other reports have confirmed their findings [73—78]; values for r2
(the proportion of variability in 1/Por that can be attributed to
variability in time) exceeded .70 in approximately 90% of
patients [78]. Fewer reports describe the pattern of decline in
GFR [71, 79—81]. Although correlations were not as high in
some studies, in general the pattern was consistent with a
constant rate of decline. Because of these high correlations,
Mitch and Walser proposed that the rate of decline in renal
function (both GFR and l/Pcr) is constant and that changes in
the rate after initiation of the treatment can be taken to
represent the consequences of treatment [3, 4].
The finding of a constant rate of decline during part of the
course of renal disease, however, does not indicate that the rate
of decline is constant throughout the entire course. For exam-
ple, consider a hypothetical patient in whom the true decline in
renal function follows the pattern of a sigmoid curve. Figure 7
shows three lines with different slopes that closely approximate
the true relationship during three time periods. Extrapolating
the slope of any of the regression lines to another period,
however, would lead to an incorrect estimate of renal function.
For a number of reasons, it is likely that the rates of decline
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and U0rV are illustrated for hypothetical patients. In the left panel, values for Ger are different but constant. Values for °er are derived from the
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woman weighing 55 kg. In (a), Ger is greatest, and initial and final values for 1/POr and rate of decline in 1/Per are least. In (d). Ger is least, and initial
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then remains constant at 1380 mg/day during the third period (from t2 to t3). The rate of decline in I/P1. is initially the same as in (a), but
subsequently it is slower and then faster than in (a).
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Fig. 7. Linear approximation to a non-linear decline in rena/function
over time. The solid curved line represents the true change in renal
function over time. The interrupted curved lines represent hypothetical
95% confidence intervals for the slopes of straight lines that approxi-
mate the curve during three time periods. Note that extrapolations of
the straight lines to earlier or later periods would not accurately reflect
the true relationship of renal function over time.
in GFR and 1'1cr are not constant throughout the entire course
of chronic renal disease. Based on possible countervailing
alterations in the determinants of SNGFR that I mentioned
earlier, it seems likely that the rate of decline in GFR in the
initial stages of renal disease is slower than in the later stages.
The determinants of 1/Per also appear to vary throughout the
course of renal disease. Maximal increases in tubular secretion
occur when renal function is minimally impaired, whereas
maximal increases in extrarenal elimination occur when renal
function is more severely impaired. Indeed, Mitch has called
attention to the fact that the rate of decline in lIP,. is not
constant if serum creatinine levels less than 2—3 mgldl are
included in the analysis of 1/Per versus time [3]. The possibility
that the rate of decline in renal function is not constant
throughout the entire course of progressive renal disease is a
clear warning that patients should not be their own controls in
studies of the effects of treatment on the rate of progression.
Instead, if the effect of treatment is to be assessed from a
comparison of the rates of decline in renal function before and
after treatment is begun, studies should include a concurrent
control group that does not receive the treatment.
Variability in the rate of decline among patients. If the rate of
decline in renal function (either GFR or 1/Per) in an individual
truly is constant over a period of time, then the slope of the
regression line would provide a precise estimate of the rate
during that interval. Because of the observed strong correla-
tions between the level of renal function and time in individuals,
the mean of the slopes of the regression lines in a study
population has been taken as an estimate of the rate of decline
in renal function of the group. However, because the rates of
decline among individuals are highly variable, the mean slope is
not a precise estimate. In the studies I have mentioned [5—9,
72—77], the mean rate of decline in i/Per ranged from approxi-
mately 0.001—0.003 dl/mglmonth, with a coefficient of variation
greater than 100%, even among patients with the same type of
renal disease. The range in rates of decline in GFR is similarly
large [79—81]. As I said earlier, because of the large variability
among patients, large sample sizes are required for clinical
trials, irrespective of the measure of renal function that is used
(Table 3).
Perhaps we can now understand why numerous treatments
appear to slow the pace of progressive renal disease in experi-
mental animals, yet none of these treatments has been proven
to be effective in humans. First, in the laboratory, variability is
reduced to a minimum. A single disease is studied in a geneti-
cally homogenous population of experimental animals. Initial
renal structure and function are either normal or are altered to
a similar extent by an identical experimental maneuver. Be-
cause treatment is initiated at the same stage of the disease in all
animals, its effect is relatively uniform. Second, it is possible to
perform invasive and repetitive assessment of renal structure
and function in the laboratory. Because the effect of treatment
is assessed by the most accurate and precise methods available,
there are few false-positive and false-negative results. Conse-
quently, the required sample size is relatively small.
In contrast, in clinical trials, variability is typically enormous.
Diverse renal diseases are studied in a diverse population. Even
in patients with the same disease, one finds a wide range of
severity of initial alterations in renal structure and function.
Furthermore, it is impossible to control rigorously other impor-
tant variables in the experimental setting. Even if treatment is
truly effective, its effectiveness is not likely to be uniform. The
type and frequency of assessments are limited to those that are
most convenient rather than to those that are most accurate or
precise, making it difficult to detect the effect of treatment. As
a result, large samples would be required; even then, negative
findings can result. The utility of a treatment might be recog-
nized only if it is highly effective in delaying progression;
partially effective treatments might be overlooked. On the other
hand, positive findings from a well-designed clinical trial should
provide relevant clinical and pathophysiologic information;
treatments that are effective in diverse patients with diverse
renal diseases are likely to interrupt a common pathogenetic
mechanism in the progression of renal disease.
Outlook
Future studies should include a longer followup interval and
also include measurements of GFR. The use of serum creatinine
or l/Per as the only measure of renal function can result in
misinterpretation of the results. In addition, we should focus
our attention on individual renal diseases, identify stages in
their progression, and identify sensitive methods for assessing
the extent of alteration in structure and function at each stage.
Several such studies of diabetic nephropathy are underway
[82]. Similar efforts are necessary in other relatively common,
well-studied diseases, such as polycystic kidney disease, mem-
branous nephropathy, and IgA nephropathy. Obviously, suc-
cessful clinical trials will require large numbers of patients,
cooperation among large numbers of institutions, and expendi-
tures of vast resources. It will be important to establish national
priorities for initiating and funding these studies [83].
In the meantime, how should we assess renal function in our
patients? Measurements of GFR using the bolus infusion and
spontaneous voiding methods, and using radioisotope-Labeled
filtration markers are accurate, precise, and simple enough for
use in clinical practice. However, because the serum creatinine
concentration is more convenient to measure, it will remain the
Time
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most widely used index of renal function in clinical practice.
Nonetheless, a greater appreciation of its limitations is neces-
sary; measurement of the serum creatinine level is an inade-
quate method for detecting chronic renal disease early and for
estimating the rate of progression, at least during short (one- to
two-year) intervals. These are serious shortcomings in view of
the considerable effort to identify therapies that can delay the
progression of chronic renal disease. If effective therapies are
found, we will need to employ more accurate measures of renal
function in routine clinical practice.
Questions and answers
DR. NICOLAOS E. MADrAS (Chief, Division of Nephrology,
New England Medical Center): You presented data on creati-
nine secretion that were mostly based on cross-sectional stud-
ies. How much do we know about creatinine secretion from
longitudinal studies in patients with progressive renal disease?
Also, is there any information about the creatine turnover rate
in patients with renal disease as opposed to normals?
DR. LEVEY: The answer to your question about creatinine
secretion is complicated for two reasons. First, it is necessary
to distinguish between the rate of tubular secretion of creatinine
(TScr, measured in mg/day) and clearance of creatinine due to
tubular secretion (Ce,. — GFR, or TScrJPcr, measured in ml/
min/ 1.73 m2). Although tubular secretion rises during chronic
renal disease, clearance due to tubular secretion rises only if the
increment in secretion is proportionately greater than the incre-
ment in the serum level. Second, it is necessary to keep in mind
the absolute level of renal function when the rate of secretion
and clearance due to secretion are measured.
In two studies that measured the rates of decline in Ccr and
GFR (assessed from clearances of radioisotope filtration mark-
ers) in patients with initial GFRs less than 60 ml/min/l .73 m2,
Ccr declined slightly faster than GFR, indicating that clearance
of creatinine due to tubular secretion also declined [71, 811. In
both studies, correlations of rates of decline in Ccr and GFR
were weak. In two other studies, serial values for Cc,. and GFR
(assessed from inulin clearances) were reported in patients with
normal initial GFR as well as patients with reduced GFR [50,
84]. In one of these studies, changes in Cer exceeded changes in
GFR [84]. In the other study, however, changes in Ccr were
slightly less than changes in GFR, and were directionally
discordant in one-half of measurements [50].
In my view, the most likely sequence of events related to
tubular secretion of creatinine is as follows: When GFR first
declines, tubular secretion is augmented, stabilizing the serum
level. Hence, clearance due to tubular secretion rises; conse-
quently, Cr declines more slowly than GFR, and the ratio of
Ccr to GFR rises. Thereafter, as GFR declines further, tubular
secretion increases further, but not in proportion to the increase
in serum level. Hence, clearance due to tubular secretion
actually declines slightly, and Ce,. declines faster than GFR.
However, because of the further decline in GFR, the ratio of Ce,.
to GFR increases further. As a result of these complex changes,
it is not possible to predict accurately changes in GFR from
changes in Ccr.
With regard to your question about creatine turnover, I am
not aware of studies on this parameter in patients with chronic
renal disease. However, an increased turnover rate has been
observed in patients with muscle diseases or malnutrition [58,
85] and in rats with infection [86]. In principle, an increased
turnover rate would lead to an initial increase in creatinine
generation. If the rate of creatine synthesis is unchanged, the
creatine pool would decline, leading to a subsequent decrease in
creatinine generation. If GFR and tubular secretion were un-
changed, the serum creatinine would initially rise and subse-
quently decline to below the baseline value.
DR. MADrAS: Have potential differences in tubular creatinine
secretion and in the relationship between GFR and creatinine
clearance been examined between patients with predominantly
tubulointerstitial diseases and those with predominantly gb-
merular diseases?
DR. LEVEY: The data that I presented in today's discussion
were derived by Shemesh and colleagues from patients with
gbomerular diseases [20]. Others have reported similar findings
in patients with a variety of renal diseases [20, 25, 49, 84,
87—103]. However, I am not aware of studies that searched for
differences among patients with gbomerular and tubulointersti-
tial diseases.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): First, how do
you weigh the three characteristics of an ideal test, either in
clinical practice or in clinical research? Second, when we have
used changes in serum creatinine as indicators of changes in
GFR, have we been too narrow? By that, I mean if one looks at
the change in serum creatinine in conjunction with other clinical
and laboratory data, such as changes in BUN, blood pressure,
urinalysis, urinary protein excretion, etc., could one identify
the patients who apparently have had normal serum creatinine
levels yet low glomerular filtration rates?
DR. LEVEY: In answer to your first question, let me empha-
size that the questions that need to be answered in clinical
practice are different from those that need to be answered in
clinical trials. In clinical practice, we need to know whether
renal function is reduced and whether it is changing. To answer
these questions, we need only determine the approximate level
of renal function; hence convenience in performing the labora-
tory test may outweigh limitations in its accuracy and precision.
In contrast, in clinical research, we need to know the exact
level and rate of change in renal function. Thus in clinical
research we need to employ more accurate and precise tests
than in clinical practice, even if they are less convenient.
In answer to your second question, let us examine the
influence of other clinical or laboratory data on the predictive
value of a normal or low serum creatinine level in indicating
normal GFR in patients with renal disease. Based on the data
presented in Figure 1, an elevated serum creatinine is 100%
specific, but only 60% sensitive. Because of the low sensitivity,
the predictive value of a normal or low serum creatinine is also
low; that is, a low proportion of patients with a normal or low
serum creatinine level have a normal GFR. Sensitivity, and
therefore predictive value, can be improved by considering
factors other than GFR that also affect the serum creatinine
level, such as age, gender, and body size, as discussed earlier.
These considerations are explicit in various formulas that can
be used to predict Ccr from 1cr [104-.-! 12]. These formulas are
not useful, however, in patients at the extremes of age and body
size, those with edema, and patients in whom the serum
creatinine changes from day to day. Another limitation is the
inaccuracy of C. as an index of GFR, as 1 discussed earlier.
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The predictive value of a negative test is also increased if the
prevalence of disease in the population to be tested is low. For
example, in a patient with normal blood pressure, normal
urinalysis, and no family history of renal disease, the likelihood
of renal disease is quite low. If the prevalence is as low as 0.5%,
then the likelihood that a patient with a normal or low serum
creatinine has a normal GFR would be 99.7%; that is, only 0.3%
of negative tests would be falsely negative. On the other hand,
in a patient with evidence of renal disease, the predictive value
of a negative test would be much lower, and more negative tests
would be falsely negative. For example, as Figure 1 shows, in
patients with glomerular disease, the predictive value of a
normal or low serum creatinine was only 40%. Thus 60% of
negative tests were falsely negative [20].
I do not doubt that the astute clinician can interpret the serum
creatinine concentration in light of considerations of creatinine
metabolism and disease prevalence and infer correctly whether
GFR is reduced and whether it is changing. It seems quite
unlikely, however, that even the most experienced nephrologist
can accurately predict the level of GFR and its rate of change
from the serum creatinine. Whether practitioners will need
more accurate and precise tests of function in the future
depends on the results of clinical trials now in progress.
DR. JEROME P. KASSIRER (Assoc. Physician-in-Chief, Dept.
of Medicine, New England Med. Ctr.): You argue that the
sensitivity of the serum creatinine as an index of renal function
is low, but of course the sensitivity of the test depends on the
cut-off point. In the study by Shemesh eta!, the cut-off point for
serum creatinine was 1.4 mg/dl [20]. I am uncomfortable with
this value because most nephrologists would consider a value
this high as norma! only for quite muscular people. If the cut-off
point were set at a lower value, the sensitivity would be higher.
DR. LEVEY: Your point is well taken. Nonetheless, a cut-off
value of only 1.2 mgldl applied to the data of She mesh et al [20]
is associated with a sensitivity of only 78%, and a predictive
value of a normal or low serum creatinine of only 53%. Thus,
47% of negative tests still would be falsely negative. Even
though nephrologists might regard a serum creatinine of 1.4
mgldl as high, I suspect that most physicians regard a slight
elevation in serum creatinine as indicating only a minimal
reduction in renal function. Clearly, this view is not warranted.
When serum creatinine is 1.4 mgldl, GFR can range from 30 to
80 ml/min/l.73 m2. The inaccuracy and imprecision are appar-
ent at lower cut-off values as well. More accurate and precise
tests are necessary to estimate the true level of renal function.
DR. RONALD PERRONE (Division of Nephrology, New En-
gland Medical Center): Your analysis of reciprocal creatinine
slopes points out the possible pitfalls: the assumption of stabil-
ity of creatinine generation, extrarenal clearance, and tubular
secretion. Yet in published studies, most patients appear to
have a constant rate of decline in reciprocal serum creatinine.
What do you think might account for this?
DR. LEVEY: It is quite clear that the correlations of reciprocal
serum creatinine versus time were very high in these reports
[72—781, suggesting that the rate of decline in reciprocal serum
creatinine is relatively constant. I suspect that the explanation
for the high correlations is as follows: (1) Because the period of
followup began only after serum creatinine was elevated, GFR
already was moderately reduced, and during the period of
followup, the further decline in GFR might have proceeded at a
relatively constant rate. (2) Because the followup interval was
relatively long (2—6 years), the effect of the decline in GFR on
serum creatinine might be quantitatively greater than the effects
of changes in creatinine secretion, extrarenal elimination, and
generation.
On the other hand, during the short intervals of followup (1—2
years) in the clinical trials I mentioned [5—9], GFR might have
declined only slightly, and serum creatinine might have been
affected more by changes in creatinine metabolism than by
changes in GFR. Hence the rate of decline in reciprocal serum
creatinine might not have been an accurate estimate of the rate
of decline in GFR in these studies.
DR. PERRONE: Perhaps selection of patients with creatinine
greater than 3 mg/dl to start with reduces the variation due to
tubular secretion, and changes in extrarenal clearance and in
generation of creatinine are small and opposite.
Let me ask another question. Your discussion concentrated
primarily on creatinine and GFR, which are markers of glomer-
ular filtration. We know from renal biopsy studies by Austin et
a! in patients with lupus nephritis that the degree of tubular
interstitial involvement is actually a more important prognosti-
cator for long-term outcome [113]. Do you know of any good
measures of tubular interstitial function other than renal biopsy
that might have predicted outcomes?
DR. LEVEY: Interestingly, the extent of tubulointerstitial
fibrosis correlates with GFR [12, 13]. Moreover, in the study by
Austin et a!, elevated serum creatinine was also an important
predictor [1131. It would have been interesting to compare the
predictive value of the GFR and the tubulointerstitial changes
observed on renal biopsy. Other tests of tubular function, such
as maximal urine concentration and ammonium excretion, also
correlate with the extent of tubulointerstitial and glomerular
damage [12, 13]. However, these factors have not been thor-
oughly examined with regard to prediction of the outcome of
chronic renal disease.
DR. MICHAEL MADAIO (Division of Nephrology, New En-
gland Medical Center): If the slopes for GFR versus time are
not constant but change over long periods of time, can we
accurately predict time to end-stage renal disease? If not,
short-term studies might be valuable in determining the effect of
therapeutic interventions on rate of decline in GFR over short
intervals but might not accurately predict the long-term effect
on the course of renal disease. In this regard, many other
supervening factors could influence the rate of progression, and
it is likely that these factors influence GFR at different times
and variably throughout the course of progression in an mdi-
vidual patient.
DR. LEVEY: Your question is an excellent one. It is extremely
important that outcome measures used in clinical trials be
validated not only for accuracy and precision, but also for
clinical significance. For example, demonstration that a dietary
intervention slows the rate of decline in GFR for a period of a
few years does not prove that the intervention prevents renal
failure. To prove that, it would be necessary to follow patients
in the trial for a longer interval to determine the frequency of
onset of renal failure or to establish the relationship between the
rate of decline in GFR and the onset of renal failure in other
patients following a similar dietary intervention.
The current NIH-supported studies of diabetic nephropathy
provide an example of the use of outcome measurements whose
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clinical significance has been extensively studied [82]. Patients
in various stages in the evolution of renal disease are being
studied, including those without any evidence of renal disease,
those with microalbuminuria, and those with clinical protein-
uria. The development of these findings in patients who did not
have them initially is considered evidence of onset and progres-
sion of renal disease. Although each study may take 5 to 10
years to complete, a study of the course to renal failure would
have required more than 20 years. Of course, this approach
required previous studies to delineate the relationships among
the stages of diabetic nephropathy.
DR. KASSIRER: Have rigorous criteria been used in assessing
the relationship between progressive renal tubular disease and
glomerular function?
DR. LEVEY: In the studies by Striker and colleagues [12, 131,
70 patients underwent renal biopsy and measurement of GFR,
renal blood flow, and urinary concentration and acidification.
Most patients had glomerular diseases. Correlation coefficients
of GFR with tubulointerstitial damage were —0.60 to —0.65,
whereas the correlation with glomerular damage was only
—0.30. Interestingly, the correlation coefficients of maximal
urinary concentration, and ammonium excretion with structural
features were even higher: —0.60 to —0.80 with tubulointersti-
tial disease and —0.35 to —0.60 with glomerular diseases.
DR. HARRINGTON: De Wardener and his colleagues also
demonstrated that the major pathologic correlate of renal failure
in patients with glomerular disease was, in fact, tubular inter-
stitial disease [1141.
Da. PAUL KURTIN (Chief, Division of Pediatric Nephro/ogy,
New England Medical Center): I have two comments. First, the
problems you have outlined in interpreting reciprocal serum
creatinine are magnified in infants and young children, who are
undergoing developmental and maturational changes in both
renal function and body composition. For example, muscle
mass increases from 25% to 40% of lean body mass in maturing
children. Second, what is the meaning of correcting renal
function for surface area, and can we be misled in interpreting
renal function by including changes of surface area that are not
related to changes in renal function? For example, the first
patient presented today lost 6 kg, which would be calculated as
a slight decrease in surface area, leading to an increase in
surface-area-adjusted GFR. Have you taken into account these
changes in surface area, and do they change in any way your
interpretation of slopes?
Da. LEVEY: I agree fully with your comments regarding
interpretation of the serum creatinine concentration in infants
and young children. In adults, small changes in weight do not
lead to changes in surface area that are sufficient to alter
adjusted values for GFR meaningfully. In the first patient,
unadjusted values for GFR were 19, 14, 13, and 12 mI/mm
during the 9-month observation period. In the second patient,
unadjusted values were 35, 28, and 22 mI/mm.
The surface area correction was introduced by Taylor,
Drury, and Addis [115] and adopted by Moller, McIntosh, and
Van Slyke to minimize variability in urea clearance results
among normal adults and children [116, 117]. This correction is
appropriate, as body surface area is more closely related to
metabolic activity and renal size than are weight or height [1181.
(The value of 1.73 m2 represents the mean surface area of men
and women 25 years of age.) Despite this adjustment, surface-
area-adjusted values for GFR in children are below adult values
until the age of 2 years [119, 120]. Flence, the use of surface area
correction in infants might not be valid. The same limitation
also might apply in populations with different body habitus.
This has particular significance in studies of renal function and
progression of renal disease in these patients. For example, in
cross-sectional studies, the normal range should be defined
from measurements of GFR in a comparable population without
renal disease. In longitudinal studies, changes should be calcu-
lated from changes in unadjusted GFR.
DR. HARRJNGTON: I was interested in your comment about
the change in serum creatinine following meat feeding. You said
that there was approximately a 0.5 mgldl rise in individuals with
normal serum creatinine levels. Do you get a larger or smaller
delta serum creatinine with meat feeding in individuals with
baseline serum creatinines in the 5—8 mg/dl range?
D. LEVEY: Because the space of distribution of ingested
creatinine (total body water) is not changed, the increment
would be expected to be similar. However, because of reduced
GFR, ingested creatinine would be excreted more slowly.
Hence, the elevation in serum creatinine might persist longer.
Because the increment in serum creatinine is proportionately
greater in individuals with a low serum creatinine concentra-
tion, the error in estimating GFR would be greatest in patients
with cr near the normal range.
DR. MADAI0: After the ingestion of a casein diet, why didn't
creatinine clearance fall? I would have expected that eating less
meat would have caused the GFR to fall in these subjects.
DR. LEVEY: First, recall that casein is a source of protein,
even though it does not contain meat. Studies by Lindheimer
and colleagues have demonstrated a rise in GFR in dogs after
casein feeding [121]. Second, the effect of dietary protein intake
on GFR in normal humans is relatively small. In the study by
1-lostetter and colleagues, the peak rise in GFR alter a large
protein load was only 10% [122]. Given the variability in Ccr01
the study by Bleiler and Schedl [651, it would have been difficult
to detect a sustained reduction in Ccr of this magnitude after
substitution of casein (if it had occurred).
DR. HARRINGTON: One of your arguments for using iothala-
mate clearance as a measure of GFR clinically was that there
might be improved clinical outcomes. One of the settings in
which this could be tested would be in patients after renal
transplantation. One could test caring for patients using simply
the delta serum creatinine in the standard fashion, versus caring
for patients with delta iothalamate clearances, and determine
whether there were a difference in outcome.
DR. LEVEY: Comparisons also could be made in the outcome
of patients receiving drugs whose doses are adjusted according
to renal function, such as cis-platinum, inethotrexate, and
aminoglycoside antibiotics.
DR. MADIAS: Going back to your points on creatinine metab-
olism, in view of the fact that there is no preformed creatinine
in muscle, what might be the reason for the more rapid rise in
serum creatinine level following rhabdomyolysis-induced acute
renal failure as compared with other types of acute renal
failure?
DR. PERRONE: A relatively recent study describes the con-
version of phosphocreatinine in muscle to creatinine and cre-
atine phosphate under physiologic conditions [123]. This mech-
anism might be accelerated in rhabdomyolysis, as this
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intermediate is sensitive to changes in pH and body tempera-
ture.
DR. MAY K. StNGH (Fe/low in Nephrology, New England
Medical Center): The observations on extrarenal elimination of
creatinine appear to be based on three human studies using a
relatively small number of patients [51, 53, 54]. Is there any
experimental evidence based on animal models that validates
these data?
DR. LEVEY: I am not aware of studies examining extrarenal
elimination of creatinine in animals with experimental renal
disease. However, extrarenal elimination can be induced in
rodents with normal renal function by feeding creatinine [124].
The hypothesized mechanism is the induction in the intestine of
bacterial enzymes capable of degrading creatinine. This same
effect might occur in patients with chronic renal disease whose
intestinal secretions contain high levels of creatinine.
Da. SINGR: It has been proposed that with a progressive
decline in GFR, the increase in extrarenal elimination of creat-
mine accounts for the reduction in renal creatinine excretion,
suggesting that creatinine generation is indeed constant [68].
Could you comment on whether any studies have confirmed
this hypothesis?
DR. LEVEY: The rate of extrarenal creatinine elimination
clearly is greater in patients with reduced renal function. In the
studies that I described earlier [53, 54], estimated rates of
creatinine generation of patients with renal disease were within
the normal range for healthy adults of similar age and gender.
The mechanism for this increase might simply be the increased
concentration of creatinine in intestinal secretions as serum
creatinine rises. This would be consistent with the constant rate
of clearance (EcrlPcr) of creatinine due to extrarenal elimination
that was observed in the study by Mitch, Collier, and Walser
[54].
DR. DEMETRIOS VLAHAROS (Fellow in Nephrology, New
England Medical Center): Changes in protein intake influence
serum creatinine by two opposing forces, namely, alterations in
creatinine and creatine intake as well as parallel changes in
GFR. In view of these counteracting mechanisms, would you
like to comment further on the relationship between serum
creatinine and GFR when employing low-protein diets in pa-
tients with chronic renal insufficiency?
DR. LEVEY: Changes in protein intake alter GFR both in
normal humans and in patients with renal disease. I already
have discussed the effect of a large protein meal on GFR and Ce,.
in normal humans. The same effect is observed in patients with
chronic renal disease; a single large meal or a sustained increase
in protein intake for one month results in an increase in GFR
and Ccr [125, 126]. Interestingly, also was increased after
protein loading in normal individuals [127], but not in patients
with chronic renal disease [126]. The converse effect is ob-
served in individuals consuming low-protein diets; in healthy
vegetarians, Cr was lower than normal [128]. Interestingly,
their serum creatinine concentrations were not elevated, pre-
sumably because of decreased intake of creatine and creatinine.
These studies highlight the effects of differences in diet on renal
function and on creatinine metabolism and the effects of
changes in the diet on these parameters. They demonstrate the
pitfalls of attempting to predict either the level, or changes in
the level, of renal function on the basis of the serum creatinine
concentration in patients with different or changing diets.
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Note added in proof
Since presentation of this Forum, IhIe et a! have reported the results
ofan important, well-designed clinical trial demonstrating the beneficial
effect of a low-protein diet to retard the progression of renal disease
[1291. In contrast to previous studies, renal function was assessed by
glomerular filtration rate (plasma clearance of 51Cr.EDTA), a control
group was included, and outcome was measured as final GFR (rather
than as rate of decline in GFR). Despite small sample size and wide
variability in final GFR within the study groups, demonstration of
efficacy was possible because of the large difference in mean final GFR
between the study groups. Most patients included in the study had
initial GFRs less than 25 mI/mm/i .73 m2. Given the wide range of values
for cr and Ccr at a GFR of 25 mlfmin/l .73 m2, it would be appropriate
to measure GFR to select patients for implementation of this diet in
clinical practice.
